Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
$0.08
-12.5%
$0.08
$0.08
$1.73
$2.44M2.011.50 million shs4.31 million shs
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
$0.13
-8.8%
$0.17
$1.75
$63.90
$297K2.15134,123 shs4.01 million shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
-50.0%
$0.00
$0.00
$0.13
$10K1.78,576 shs15,514 shs
Quotient Limited stock logo
QTNT
Quotient
$0.44
$0.18
$105.20
$980K2.32437,886 shs5.81 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
0.00%0.00%0.00%-22.05%-93.83%
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
-8.79%-10.23%-28.04%-65.14%-93.36%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-50.00%-50.00%-87.50%-75.00%-50.00%
Quotient Limited stock logo
QTNT
Quotient
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
0.8401 of 5 stars
3.50.00.00.00.00.00.0
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
3.00
Buy$5.506,607.32% Upside
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
0.00
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
$9.18M0.27N/AN/A($0.23) per share-0.36
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
N/AN/AN/AN/A$7.21 per shareN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K1.23N/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
$38.51M0.00N/AN/A($56.17) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
-$16.69M-$0.98N/AN/A-165.07%N/A-267.23%8/11/2025 (Estimated)
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
-$4MN/A0.00N/AN/A-179.05%-108.14%N/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18MN/A0.00N/AN/AN/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
-$125.13M-$53.21N/AN/AN/A-413.55%N/A-88.21%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
$1.041,268.29%N/AN/A N/A
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
N/A
0.75
0.70
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
N/A
0.62
0.62
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A
Quotient Limited stock logo
QTNT
Quotient
N/A
1.79
1.36

Institutional Ownership

CompanyInstitutional Ownership
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
12.19%
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
9.64%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%
Quotient Limited stock logo
QTNT
Quotient
N/A

Insider Ownership

CompanyInsider Ownership
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
4.30%
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
2.12%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
Quotient Limited stock logo
QTNT
Quotient
10.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aspira Women's Health Inc. stock logo
AWH
Aspira Women's Health
11029.76 million16.92 millionNo Data
MyMD Pharmaceuticals, Inc. stock logo
MYMD
MyMD Pharmaceuticals
62.37 million2.32 millionOptionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionOptionable
Quotient Limited stock logo
QTNT
Quotient
4262.58 million2.31 millionOptionable

Recent News About These Companies

Glam Quotient At Ayodhya
Partial Quotient Division
How to Refresh Your Creativity Quotient
Quotient (NASDAQ: QTNT)
Adventure Quotient (AQ) Test
Vid boys in Dungarpur Trophy SF - The Hitavada
Quotient Tech: Q1 Earnings Snapshot - Times Union

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aspira Women's Health stock logo

Aspira Women's Health NASDAQ:AWH

$0.08 -0.01 (-12.49%)
As of 04/16/2025

Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.

MyMD Pharmaceuticals stock logo

MyMD Pharmaceuticals NASDAQ:MYMD

$0.13 -0.01 (-8.79%)
As of 06/26/2025

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

$0.0001 0.00 (-50.00%)
As of 06/27/2025 03:04 PM Eastern

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Quotient stock logo

Quotient NASDAQ:QTNT

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.